
News|Videos|October 30, 2026
AAPS 2026 PharmSci 360 Video Recap: AI Transparency, Oral Peptides, and New Models
This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
Advertisement
Advertisement
This year’s American Association of Pharmaceutical Scientists’s (AAPS) 2026
Related to this article

Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.

This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.

FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.

Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.

Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.

HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.

DAX-044 aims to confine IL-12 activity to tumors and avoid the toxicity that has limited IL-12 therapy, with phase 1 testing expected in 2027.
Advertisement
Advertisement

